A Study of Ixekizumab in Healthy Participants

Completed · Phase 1

Conditions studied: Healthy

In brief

The purpose of this study is to compare three different formulations of ixekizumab. One formulation (Reference) has been approved by the Food and Drug Administration (FDA) and two formulations (Test 1 and Test 2) have not been approved. This study will compare how much of each of the three formulations get into the blood stream. Information about any side effects that may occur will also be collected.

Key facts

Study ID
NCT03848416
Run by
Eli Lilly and Company
People needed
99
Starts
2019-01-29
Expected to finish
2019-06-07
Last updated by the study team
2020-06-24

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.